Halozyme Therapeutics Inc. (NASDAQ:HALO)’s share price was up 2.4% on Wednesday . The stock traded as high as $9.89 and last traded at $9.75, with a volume of 553,054 shares changing hands. The stock had previously closed at $9.52.

Several equities analysts have recently weighed in on HALO shares. Jefferies Group restated a “sell” rating and set a $6.75 price objective on shares of Halozyme Therapeutics in a research report on Tuesday, May 10th. Piper Jaffray Cos. reiterated an “overweight” rating and issued a $15.00 target price on shares of Halozyme Therapeutics in a report on Thursday, June 23rd. Wells Fargo & Co. reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday, June 8th. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $11.00 target price on shares of Halozyme Therapeutics in a report on Monday, June 6th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company. Halozyme Therapeutics presently has a consensus rating of “Buy” and an average target price of $15.68.

The company’s market capitalization is $1.27 billion. The stock has a 50 day moving average price of $8.87 and a 200-day moving average price of $9.35.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.20) by $0.04. The business earned $42.50 million during the quarter, compared to the consensus estimate of $29.65 million. During the same period in the prior year, the firm earned ($0.12) earnings per share. The business’s quarterly revenue was up 127.3% compared to the same quarter last year. On average, equities research analysts anticipate that Halozyme Therapeutics Inc. will post ($1.03) EPS for the current fiscal year.

Several hedge funds and institutional investors have added to or reduced their stakes in HALO. Nationwide Fund Advisors boosted its position in Halozyme Therapeutics by 2.3% in the fourth quarter. Nationwide Fund Advisors now owns 69,817 shares of the biopharmaceutical company’s stock worth $1,210,000 after buying an additional 1,563 shares in the last quarter. California State Teachers Retirement System boosted its position in Halozyme Therapeutics by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 196,510 shares of the biopharmaceutical company’s stock worth $3,406,000 after buying an additional 3,096 shares in the last quarter. California Public Employees Retirement System boosted its position in Halozyme Therapeutics by 10.2% in the fourth quarter. California Public Employees Retirement System now owns 255,600 shares of the biopharmaceutical company’s stock worth $4,430,000 after buying an additional 23,600 shares in the last quarter. New York State Common Retirement Fund boosted its position in Halozyme Therapeutics by 5.4% in the fourth quarter. New York State Common Retirement Fund now owns 372,785 shares of the biopharmaceutical company’s stock worth $6,460,000 after buying an additional 18,940 shares in the last quarter. Finally, BB Biotech AG boosted its position in Halozyme Therapeutics by 1.4% in the fourth quarter. BB Biotech AG now owns 7,029,832 shares of the biopharmaceutical company’s stock worth $121,827,000 after buying an additional 100,000 shares in the last quarter.

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of enzymes segment. This segment also includes research and development, and bulk rHuPH20 manufacturing activities conducted under its collaborative agreements with third parties, and product sales of Hylenex recombinant.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.